Vasa Denticity MD, chairman, board of directors and AGM
NSE: DENTALKARTHealthcare Equipment & Supplies
Share price at the NSE close on 23 Oct 2026. Previous close ₹454.10.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹794 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 1 Jul 2026
- 4.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 1 Jul 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 49,75069.9% delivered
Vasa Denticity board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- KRA & Co.Peer-review certificate valid to Sep 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Vasa Denticity AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Vasa Denticity share news and announcements
Annual general meeting, 29 Sep 2026
2,647 shareholders on the register on 22 Sep 2026; present: 1 promoter and 27 others; votes counted by Loveneet Handa / Loveneet Handa and Associates.The company's voting result (opens in a new tab)
To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended on March 31, 2026, including the Audited Balance Sheet as of March 31, 2026, the Statement of Profit and Loss and the Cash Flow Statement for the year ended on that date together with the reports of the Board of Directors and the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
To receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the Financial Year ended on March 31 2026, including the Audited Balance Sheet as at March 31 2026, the Statement of Profit and Loss and the Cash Flow Statement for the year ended on that date together with the reports of the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To appoint a director in place of Mr. Sandeep Aggarwal (DIN: 07484533), who retires by rotation and being eligible, offers himself for reappointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To take note of and ratify the mutual cancellation of the proposed acquisition of an additional 31.08% and equity stake in IDS Denmed Private Limited.Special99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 36.06%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.
Mutual fund votes, meeting of 26 Sep 2025, 1 fund house
Appointment of M/s Naresh Verma and Associates (FCS 5403 (COP No. 4424). Peer Review Certificate No.: 3266/2023 as the Secretarial Auditor of the Company for a period of five (5) consecutive financial years, commencing from April 1, 2025, until March 31, 2030, to conduct Secretarial Audit of the Company and to furnish the Secretarial Audit Report.MoreLess
1 for0 against- To appoint a director in place of Dr. Akanksha Aggarwal (DIN:10056201), Non-Executive Director of the company, who retires by rotation and being eligible, offers herself for reappointment.1 for0 against
- To consider and approve the regularisation of Dr. Rohan Kaushikbhai Bhatt (DIN: 10799309) as a Director (Non-Executive) of the Company, liable to retire by rotation.1 for0 against
To, inter alia, (a) give any loan to any person(s) or other body corporate(s),(b)give any guarantee or provide security in connection with a loan to any person(s) or other body corporate(s), and (c) acquire by way of subscription, purchase or otherwise, securities of any other body corporate from time to time in one or more tranches as the Board of Directors as in their absolute discretion deem beneficial and in the interest of the Company from time to time, shall not exceed, at any time Rs. 200 Crores over and above the limit of sixty per cent of the paid up share capital, free reserves and securities premium account of the Company or one hundred per cent of free reserves and securities premium account of the Company, whichever is more.MoreLess
1 for0 againstTo receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the Financial Year ended on March 31, 2025, including the Audited Balance Sheet as of March 31, 2025, the Statement of Profit and Loss and the Cash Flow Statement for the year ended on that date together with the reports of the Board of Directors and the Auditors thereon.MoreLess
1 for0 againstTo receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended on March 31, 2025, including the Audited Balance Sheet as of March 31, 2025, the Statement of Profit and Loss and the Cash Flow Statement for the year ended on that date together with the reports of the Board of Directors and the Auditors thereon.MoreLess
1 for0 against
Mutual fund votes, meeting of 25 Aug 2025, 1 fund house
To create offer, issue allot and deliver in one or more tranches up to 12,34,185 Equity Shares of Rs. 10/- at a price of Rs. 632/- per Equity Share on a preferential basis (Preferential Allotment Price), aggregating to not exceeding Rs. 78,00,04,920/-, which is not less than the price determined in accordance with Chapter V of the SEBI ICDR Regulations (hereinafter referred to as the Floor Price), for consideration other than cash (i.e. swap of shares of Proposed Allottee as listed in the below table) towards payment of the total consideration payable for the acquisition of 15,538 Equity Shares representing 31.08% shareholding of the IDS Denmed Private Limited (IDS Denmed or Target Company) on a preferential basis (Preferential Allotment), to the Non-Promoter categories of persons.MoreLess
1 for0 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
The company's own answers in its filing.